Afatinib (BIBW 2992) slide kit

Boehringer Ingelheim

BIBW 2992 is a potent, irreversible inhibitor of EGFR/HER1 and HER2,^1,2 one of the most advanced inhibitors of this type in development. It is active in NSCLC cells harbouring EGFR mutations sensitive and insensitive to first generation TKIs².

BIBW 2992 also provides activity against receptors that are insensitive to first-generation inhibitors (e.g. EGFRL858R/T790M mutants).

References
1. Eskens FALM et al. Br J Cancer 2008; 98:80–85
2. Li D et al. Oncogene 2008; 27: 4702–4711

Items: 10

Summary of LUX Lung 1 clinical trial

Lux lung 5 phase 3 clinical trial

Pathways in EGFR and HER signaling

Epidermal growth factor (EGF) receptors

BIBW 2992 cancer treatment data presented at ASCO

LUX Lung 2 clinical cancer trial

Better lung cancer treatments

LUME-Lung 1 Infographic

LUX-Lung 2 and 3 cancer clinical trial

Cancer statistics and incidence rates

Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.

† Not an official event of the 2012 ASCO Annual Meeting. Not sponsored or endorsed by ASCO or the Conquer Cancer Foundation.

Boehringer Ingelheim on